Medicare Transaction Fraud Prevention Act
- Bill Number
- H.R. 3996
- Origin Chamber
- House
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-06-12: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- Last Updated
- 2025-12-05T22:04:59Z
AI-Generated Summary
Purpose
The Medicare Transaction Fraud Prevention Act (H.R. 3996) aims to reduce fraud and abuse in Medicare payments by establishing a two-year pilot program. This program tests a predictive risk-scoring algorithm—a computer tool that analyzes data to assign risk levels to certain claims—to oversee payments for durable medical equipment (DME, such as wheelchairs or oxygen tanks) and clinical diagnostic laboratory tests (like blood work).
Key Provisions
- Pilot Program Setup: The U.S. Department of Health and Human Services (HHS) Secretary must launch the program by January 1, 2026, for a duration of two years. It focuses on claims (called "relevant transactions") for DME or lab tests provided to "applicable beneficiaries"—Medicare enrollees who voluntarily opt in and agree to receive electronic Medicare Summary Notices (monthly statements of benefits and payments).
- Voluntary Participation: Beneficiaries can join or leave the program at any time, ensuring it's optional.
- Risk Assessment Factors: The algorithm evaluates risks based on indicators like:
- No previous relationship between the beneficiary and the provider (e.g., doctor) or supplier (e.g., equipment vendor).
- Unusual billing patterns, such as a high volume of claims from one area.
- Changes in electronic fund transfers (how payments are sent) or ownership of providers/suppliers.
- Algorithm Development and Use:
- The algorithm scores transactions from 1 (lowest risk) to 99 (highest risk) using beneficiary data.
- Before use, it must undergo testing, evaluation, and review, considering Executive Order 14179 (which promotes U.S. leadership in artificial intelligence by reducing barriers).
- HHS must collaborate with industry groups, including DME suppliers, and communicate with the HHS Office of the Inspector General (OIG, an internal watchdog for fraud).
- Beneficiaries and providers must be notified about data use, risk scoring, and implications.
- Handling High-Risk Claims:
- For scores above a threshold set by the Secretary, HHS reviews the claim and may suspend payment temporarily.
- Beneficiaries can respond by email or phone to correct errors or confirm the claim.
- If suspended, beneficiaries receive automatic electronic alerts via Medicare Summary Notices every two weeks for three months, including tips on reporting fraud to law enforcement.
- Suspensions require human review, not just the algorithm's output.
- Additional Authority: HHS can terminate or reissue Medicare cards to prevent fraud.
- Definitions:
- "Applicable items or services": DME and clinical lab tests.
- "Relevant transaction": A payment claim for these items/services to an opted-in beneficiary.
Significant Changes to Existing Law
This bill amends Section 1128K of the Social Security Act (which addresses Medicare fraud and abuse) by:
- Updating the section's heading to include the new pilot program.
- Adding a new subsection (d) that introduces the predictive risk-scoring pilot specifically for DME and lab test payments. Previously, this section focused on general fraud prevention without mandating AI-based tools or voluntary beneficiary involvement for such oversight.
No broader changes to Medicare payment rules are made; the pilot is limited and experimental.
Potential Impacts
- On Government Agencies: The Centers for Medicare & Medicaid Services (CMS, part of HHS) could improve fraud detection efficiency, potentially saving taxpayer money by flagging suspicious claims early. It may increase administrative workload for testing, notifications, and reviews but builds on existing electronic systems.
- On Citizens: Opted-in Medicare beneficiaries gain tools to monitor and report potential fraud, such as faster alerts about suspicious claims, but face more frequent electronic notices. Non-opted-in individuals are unaffected, preserving choice. Providers and suppliers might experience payment delays for high-risk claims, encouraging better compliance.
- On International Relations: No direct impacts, as the bill is domestic and focused on U.S. Medicare operations.
Main Stakeholders Affected
- Medicare Beneficiaries: Especially those using DME or lab tests, who must opt in for participation and may interact more with electronic notices.
- Healthcare Providers and Suppliers: Doctors, hospitals, DME vendors, and labs submitting claims, who could face reviews or delays and must collaborate on program development.
- Government Entities: HHS Secretary and CMS (implementing the pilot); OIG (for fraud coordination); Congress (via oversight committees like Energy and Commerce and Ways and Means).
- Industry Groups: DME suppliers and lab testing companies, involved in designing the algorithm to ensure practicality.
Notable Legal, Constitutional, or Political Implications
- Legal: Strengthens existing Medicare anti-fraud tools under the Social Security Act by integrating data-driven technology, with built-in safeguards like human review and beneficiary appeals to avoid erroneous suspensions. It aligns with federal efforts to combat healthcare fraud, estimated to cost billions annually.
- Constitutional: The voluntary opt-in protects privacy rights (e.g., under the Fourth Amendment) by requiring consent for data use and notifications. No mandatory surveillance is imposed, reducing risks of overreach.
- Political: As an introduced bill (not yet law), it reflects priorities for modernizing Medicare with AI while emphasizing testing and industry input, potentially appealing across party lines for fiscal responsibility. Referral to key committees suggests focus on health policy and budgeting, with no overt partisan elements in the text.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Rep. Schweikert, David [R-AZ-1]
Recent Actions
- 2025-06-12: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2025-06-12: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2025-06-12: Introduced in House
- 2025-06-12: Introduced in House
Bill Versions
- Medicare Transaction Fraud Prevention Act — issued 2025-06-12 — PDF (8 pages)